Sofosbuvir: Clinical Trials

14 trials of Sofosbuvir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 unknown. 14 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 314Unknown 14
Phase 26Unknown 6

Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children
Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV
Phase 3UnknownAin Shams University302022-06-052023-05-11
Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)
Sofosbuvir 400 MG plus Daclatasvir 200mg - COVID-19
Phase 3UnknownMansoura University502020-12-282021-02-24
Sofosbuvir in Treatment of COVID 19
sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID
Phase 2 / Phase 3UnknownTanta University602020-08-012020-12-08
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
Sofosbuvir, Daclatasvir - Covid19
Phase 2 / Phase 3UnknownTanta University1002020-07-012020-12-03
Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19
Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19
Phase 2 / Phase 3UnknownCairo University1002020-07-012020-06-25
Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients
Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c
Phase 3UnknownAssiut University502019-09-012019-09-12
Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients
Seraprevir, Sofosbuvir - Hepatitis C Virus Infection
Phase 3UnknownGinkgopharma CO., LTD2062018-10-172019-06-28
Effect of Direct-acting Antiviral Drugs on Erectile Function
Sofosbuvir and Daklatasuvir - Hepatitis C
Phase 3UnknownSherief Abd-Elsalam1052018-01-012020-10-22
Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
Daclatasvir and sofosbuvir - Chronic HCV Infection
Phase 2 / Phase 3UnknownAin Shams University502017-12-102023-03-06
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg) - Hepatitis C Virus Infection, Response to Therapy of
Phase 3UnknownEgyptian Liver Hospital802017-04-152018-05-24
Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients
Sofosbuvir/Ledipasvir 12W, Sofosbuvir/Ledipasvir plus Ribavirin 12W, Sofosbuvir/Ledipasvir 24W - Hepatitis C
Phase 3UnknownIran Hepatitis Network2002017-03-012017-02-23
Strategic Transformation of the Market of HCV Treatments
sofosbuvir + ravidasvir - Hepatitis C
Phase 2 / Phase 3UnknownDrugs for Neglected Diseases6032016-09-012021-01-20
The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach
Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) - Hepatitis C, Drug Abuse, Intravenous
Phase 3UnknownMacfarlane Burnet Institute for Medical Research and Public Health Ltd4202015-02-012018-04-10
A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
ravidasvir hydrochloride, sofosbuvir, ribavirin - Chronic Hepatitis C
Phase 2 / Phase 3UnknownPharco Pharmaceuticals3002015-01-012016-04-07

Conditions studied

Hepatitis C (6)  ·  COVID-19 (3)  ·  Hepatitis C, Chronic (2)  ·  Hepatitis (1)  ·  Substance Abuse, Intravenous (1)

Sponsors

Ain Shams University (2)  ·  Tanta University (2)  ·  Assiut University (1)  ·  Cairo University (1)  ·  Drugs for Neglected Diseases (1)  ·  Egyptian Liver Hospital (1)  ·  Ginkgopharma CO., LTD (1)  ·  Iran Hepatitis Network (1)  ·  Macfarlane Burnet Institute for Medical Research and Public Health Ltd (1)  ·  Mansoura University (1)  ·  Pharco Pharmaceuticals (1)  ·  Sherief Abd-Elsalam (1)

Countries

Egypt (9)  ·  Australia (1)  ·  China (1)  ·  Malaysia (1)  ·  Thailand (1)

Top investigators

Ahmed Cordie, lecturer (1)  ·  Bita Behnava, MD (1)  ·  Gamal Esmat, M.D. (1)  ·  Gamal Esmat, Professor (1)  ·  Gamal Shiha, MD (1)  ·  Heidar Sharafi, PhD (1)  ·  Isabelle Andrieux-Meyer, MD (1)  ·  Khaled Almekaty, MD (1)  ·  Manal H El-Sayed, MD (1)  ·  Manal H. El-Sayed, MD (1)  ·  Marwa Salama, Consultant (1)  ·  Marwa Salama, Lecturer (1)  ·  Mohamed Alhefnawy, MD (1)  ·  Mohammad Saeid Rezaee-Zavareh, MD (1)  ·  Prof Alexander Thompson (1)

Results publications

PMID 28935432, PMID 31999307, PMID 32367815, PMID 33865507